Related Experiment Video
Updated: Aug 13, 2025
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.3K
MTA1 as negative prognostic marker in vulvar carcinoma
Giulia Wanka1, Julia Jueckstock2,3, Carl Mathis Wild1
1Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstraße 2, 86156, Augsburg, Germany.
Journal of Cancer Research and Clinical Oncology
|January 23, 2023
Summary
Metastasis-associated gene 1 (MTA1) expression is linked to poorer outcomes in vulvar cancer. High nuclear MTA1 correlates with advanced disease, while its absence predicts lower disease-free survival, identifying it as a negative prognostic marker.
Area of Science:
- Gynecologic Oncology
- Cancer Biomarkers
- Molecular Pathology
Background:
- Vulvar cancer is a rare gynecologic malignancy primarily affecting elderly women.
- Limited data exists on targeted therapies and predictive biomarkers for vulvar carcinoma.
- Metastasis-associated gene 1 (MTA1) is implicated in the progression of other gynecologic cancers.
Purpose of the Study:
- To investigate the expression of MTA1 in vulvar carcinoma tissues.
- To correlate MTA1 expression with clinicopathological characteristics.
- To evaluate MTA1 as a prognostic marker for vulvar carcinoma.
Main Methods:
- Immunohistochemical staining for MTA1 expression in 157 vulvar cancer tissues.
- Quantification of MTA1 expression using the immunoreactive score.
- Correlation analysis with clinicopathological parameters and patient survival.
Main Results:
- MTA1 was expressed in the cytoplasm (94%) and nucleus (91%) of vulvar cancer tissues.
- Increased cytoplasmic MTA1 was observed in non-keratinizing and condylomatous types.
- High nuclear MTA1 expression correlated with advanced tumor size and higher FIGO grading.
- Absence of nuclear MTA1 expression was associated with significantly lower disease-free survival.
Conclusions:
- MTA1 serves as a negative prognostic marker in vulvar carcinoma.
- Its expression is linked to advanced tumor stage and grade.
- The study suggests a potential role for MTA1 in predicting early recurrence, possibly due to antibody binding issues with specific mutations.
